A
Amy Kerrigan
Researcher at Vanderbilt University
Publications - 8
Citations - 1064
Amy Kerrigan is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Latent tuberculosis & Rifapentine. The author has an hindex of 5, co-authored 7 publications receiving 840 citations.
Papers
More filters
Journal ArticleDOI
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling,M. Elsa Villarino,Andrey S. Borisov,Nong Shang,Fred M. Gordin,Erin Bliven-Sizemore,Judith Hackman,Carol Dukes Hamilton,Dick Menzies,Amy Kerrigan,Stephen E. Weis,Marc H Weiner,Diane Wing,Marcus Barreto Conde,Lorna Bozeman,C. Robert Horsburgh,Richard E. Chaisson +16 more
TL;DR: The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniaZid alone in preventing tuberculosis and had a higher treatment-completion rate.
Journal ArticleDOI
PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
Lindsay J. Celada,Jonathan A. Kropski,Jose D. Herazo-Maya,Weifeng Luo,Amy Creecy,Andrew T. Abad,O.S. Chioma,Grace Lee,Natalie E. Hassell,Guzel Shaginurova,Yufen Wang,Joyce E. Johnson,Amy Kerrigan,Wendi R. Mason,Robert P. Baughman,Gregory D. Ayers,Gordon R. Bernard,Daniel A. Culver,Courtney G. Montgomery,Courtney G. Montgomery,Toby M. Maher,Toby M. Maher,Philip L. Molyneaux,Philip L. Molyneaux,Imre Noth,Steven E. Mutsaers,Cecilia M. Prêle,R. Stokes Peebles,Dawn C. Newcomb,Naftali Kaminski,Timothy S. Blackwell,Luc Van Kaer,Wonder P. Drake +32 more
TL;DR: A critical, previously unrecognized role is identified for PD-1+CD4+ T cells in pulmonary fibrosis, supporting the use of readily available therapeutics that directly address interstitial lung disease pathophysiology.
Journal ArticleDOI
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
D. Shepardson,Suzanne M. Marks,H. Chesson,Amy Kerrigan,David P. Holland,Nigel A. Scott,X. Tian,Andrey S. Borisov,Nong Shang,Charles M. Heilig,Timothy R. Sterling,Margarita E. Villarino,W. R. Mac Kenzie +12 more
TL;DR: 3HP may be a cost-effective alternative to 9H, particularly if the cost of rifapentine decreases, the effectiveness of 3HP can be maintained without DOT, and 3HP treatment is limited to those with a high risk of progression to TB disease.
Journal ArticleDOI
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada
Ruth N. Moro,Andrey S. Borisov,Jussi J. Saukkonen,Awal Khan,Timothy R. Sterling,M. Elsa Villarino,Nigel A. Scott,Nong Shang,Amy Kerrigan,Stefan V. Goldberg +9 more
TL;DR: Factors associated with NCT, such as missing a clinic visit early during treatment, might help identify persons for whom tailored interventions could improve completion of LTBI treatment.
Journal ArticleDOI
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.
A. Jayakumar,Radojka M. Savic,Charles K. Everett,Debra Benator,David Alland,Charles M. Heilig,Marc H Weiner,Sven O. Friedrich,Neil A. Martinson,Amy Kerrigan,Carlos Zamudio,Stefan V. Goldberg,William C. Whitworth,J. L. Davis,Payam Nahid +14 more
TL;DR: The data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response as well as a sensitive and specific as a diagnostic test.